DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Enoticumab
Enoticumab
Precision Medicine for Human Cancers with Notch Signaling Dysregulation (Review)
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Form 10-Q Regeneron Pharmaceuticals, Inc
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
In Patients with Previously Treated Solid Tumors
The Role of Tumor Microenvironment in Resistance to Anti-Angiogenic
(INN) for Biological and Biotechnological Substances
New Horizons in Tumor Microenvironment Biology: Challenges and Opportunities Chen Et Al
Original Article Two Engineered Site-Specific Antibody-Drug Conjugates, Hlmd4 and Hlvm4, Have Potent Therapeutic Activity in Two DLL4-Positive Tumour Xenograft Models
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
14-350 Phrma Cancer2014 1001.Indd
Ovarian Cancer Stem Cells and Targeted Therapy
WO 2017/176762 Al 12 October 2017 (12.10.2017) P O P C T
(INN) for Biological and Biotechnological Substances
Signalling Pathways Regulating Organ-Specific Endothelial
Top View
Strategies to Obtain Diverse and Specific Human Monoclonal
6.6.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
A Phase I First-In-Human Study of Enoticumab (REGN421), a Fully-Human Delta-Like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Non-Small Cell Lung Cancer
A Phase I First-In-Human Study of Enoticumab
Challenges to Cure Cancer
A Phase I First-In-Human Study of Enoticumab (REGN421), a Fully-Human Delta-Like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Non-Small Cell Lung Cancer
Top Notch Targeting Strategies in Cancer: a Detailed Overview of Recent Insights and Current Perspectives
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
A Phase I First-In-Human Study of Enoticumab
WO 2015/038818 A2 19 March 2015 (19.03.2015) P O P C T
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) 按照专利合作条约所公布的国际申请w O 2016/050208
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
WO 2017/189679 Al 02 November 2017 (02.11.2017) W !P O PCT